How to Get Repatha (Evolocumab) in Connecticut

What Is Repatha and Why Connecticut Patients Pursue It

Repatha is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab allows the liver to clear more LDL-C from the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

The FOURIER trial (N=27,564) reported that adding evolocumab 140 mg every two weeks or 420 mg monthly to statin therapy reduced LDL-C by 59% from baseline and cut the risk of the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% over a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79-0.92, P<0.001). [2]

Connecticut has roughly 3.6 million residents, and the CDC estimates that approximately 7% of U.S. adults have familial hypercholesterolemia or markedly elevated LDL-C requiring therapy beyond statins. [3] That translates to tens of thousands of Connecticut residents who may be candidates for evolocumab yet remain untreated because they do not know how to manage the prescription and authorization process.

Who Can Prescribe Repatha in Connecticut

Any licensed Connecticut prescriber with DEA authority may write a Repatha prescription. That includes MDs, DOs, nurse practitioners (APRNs) with prescriptive authority, and physician assistants (PAs) practicing under a collaboration agreement. [4] Connecticut APRNs hold full prescriptive authority for Schedule II through V controlled substances and for non-controlled medications, meaning they do not need physician co-signature for a Repatha Rx.

Cardiologists and lipidologists are the most common prescribers because evolocumab indications overlap with their patient populations. Endocrinologists frequently prescribe it for HeFH patients. Primary care physicians, internists, and advanced practice providers may also prescribe it once they document the qualifying indication and a prior authorization is submitted.

The ACC/AHA 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy." [5] That threshold gives Connecticut prescribers a clear clinical trigger they can document in the chart before submitting prior authorization.

Telehealth prescribers licensed in Connecticut can initiate a Repatha prescription during a video or asynchronous visit. Connecticut's telehealth parity law requires that commercial insurers reimburse telehealth-initiated prescriptions equivalently to in-person prescriptions, which removes a historical barrier to remote access. [6]

Labs and Clinical Documentation Required Before Prescribing

Most Connecticut insurers and CT Medicaid (HUSKY Health) require documented evidence that the patient has an eligible diagnosis and has already tried and failed to reach LDL-C goals on statin therapy before they will authorize evolocumab. Getting the right labs upfront prevents delays.

Baseline labs typically required:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) drawn within the past 90 days
• Repeat fasting lipid panel on maximally tolerated statin (with or without ezetimibe)
• Liver function tests (AST, ALT) to establish baseline hepatic safety
• CK (creatine kinase) if statin intolerance is being documented
• TSH if secondary hypercholesterolemia from hypothyroidism has not been excluded

The FDA label for evolocumab notes no specific contraindications based on liver enzyme thresholds, but insurers still request LFTs as part of PA documentation. [1] A fasting lipid panel that shows LDL-C at or above 70 mg/dL despite documented statin use is the single most critical piece of evidence in the PA package. Patients who cannot tolerate statins must provide documentation of at least two statin trials at different doses or with different agents, ideally supported by a clinician note or a CK result during a symptomatic episode. [7]

HealthRX Connecticut Prescribing Pathway for Evolocumab:

1. Confirm qualifying diagnosis (HeFH, HoFH, or established ASCVD) with ICD-10 code (E78.01 for HeFH, E78.02 for HoFH, or relevant ASCVD code).
2. Order or obtain a fasting lipid panel and LFTs within 90 days.
3. Document current or prior statin therapy with dose and duration; record any statin intolerance with supporting evidence.
4. Add ezetimibe 10 mg daily if not already prescribed; document response (or intolerance).
5. Confirm LDL-C remains at or above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH without ASCVD) per ACC/AHA thresholds. [5]
6. Submit PA to insurer with all above documentation plus the prescriber's NPI and the drug's J-code (J0595 for the 140 mg/mL single-dose prefilled autoinjector).
7. If denied, initiate a peer-to-peer review call within the insurer's appeal window (usually 30 days).

How to Get a Repatha Prescription via Telehealth in Connecticut

Connecticut telehealth prescribing for Repatha is fully permissible. A Connecticut-licensed provider can evaluate a patient by video, review uploaded lab results and prior records, and transmit an electronic prescription directly to a specialty pharmacy. The patient never needs to leave home to initiate treatment. [6]

The evaluation must still meet the same clinical standards as an in-person visit. The provider needs to verify identity, review the medication list, document the qualifying indication, confirm the most recent fasting lipid panel, and assess contraindications. A telehealth visit that takes 20 to 30 minutes is sufficient for a straightforward ASCVD or HeFH case with labs already in hand.

For patients without recent labs, many Connecticut telehealth platforms can route a standing lab order to a nearby Quest Diagnostics or LabCorp draw site. Results typically return within 24 to 48 hours, allowing the prescriber to complete the clinical review and submit the PA without an additional visit.

The European Society of Cardiology 2019 guidelines note that PCSK9 inhibitors should be considered for very-high-risk patients who do not achieve LDL-C goals with statins and ezetimibe, regardless of care delivery model, reinforcing that telehealth-initiated prescribing aligns with evidence-based targets. [8]

Prior Authorization in Connecticut: What Plans Require

Prior authorization is the most common barrier Connecticut patients face. Commercial insurers in Connecticut (Anthem/BCBS CT, Aetna, Cigna, United, ConnectiCare) and HUSKY Health (CT Medicaid) all require PA for evolocumab. The documentation package typically includes:

• Signed letter of medical necessity from the prescriber
• Evidence of qualifying diagnosis with ICD-10 code
• Two or more fasting lipid panels showing inadequate LDL-C control
• Documentation of statin trial(s) at maximally tolerated dose for at least 4 to 12 weeks
• Documentation of ezetimibe trial (most plans require this as a step-therapy agent)
• Current medication list
• Prescriber's NPI and Connecticut state license number

Connecticut Medicaid covers evolocumab for FH and established ASCVD with PA approval. [9] The state's step-therapy requirements generally mirror those published by the Institute for Clinical and Economic Review (ICER), which conducted a 2017 cost-effectiveness review concluding that evolocumab met standard willingness-to-pay thresholds when used in very-high-risk patients. [10]

Approval turnarounds vary. Anthem CT targets 3 business days for standard PA and 1 business day for urgent requests. HUSKY Health typically processes PA requests in 5 to 10 business days. If the initial PA is denied, a peer-to-peer call between the prescriber and the plan's medical director resolves the majority of first-level denials in published studies examining PCSK9 inhibitor access. [11]

Cost assistance: Amgen's Repatha Copay Card can reduce out-of-pocket costs to as low as $5 per month for commercially insured patients who qualify. Amgen's patient assistance program (AVONEX/Repatha SUPPORT) covers uninsured and underinsured Connecticut residents. [1]

Specialty Pharmacy Access and Delivery in Connecticut

Evolocumab is dispensed exclusively through specialty pharmacies. It requires cold-chain shipping (2-8°C) and is not stocked on standard retail pharmacy shelves. Major specialty pharmacies that serve Connecticut residents include Accredo (Express Scripts), CVS Specialty, Optum Specialty, and Walgreens Specialty. Amgen's own CareAssist program connects patients directly to a preferred specialty pharmacy after approval.

Once the PA is approved and the prescription is transmitted, specialty pharmacies typically ship within 2 to 5 business days. Patients receive the medication in an insulated cold pack with ice packs sufficient for up to 72 hours of transit. Repatha can be stored at room temperature (up to 77°F/25°C) for up to 30 days if patients prefer to keep a supply outside the refrigerator. [1]

For patients already established on Repatha in another state who are relocating to or newly insured in Connecticut, prescription transfers are straightforward. The specialty pharmacy needs only the new insurance information and a confirmed Connecticut-licensed prescriber on record. If the patient switches insurers, a new PA will be required even if the previous insurer already approved the medication.

503A compounding pharmacies licensed in Connecticut may prepare PCSK9-related formulations with a valid, patient-specific prescription from a Connecticut-licensed prescriber. Compounded evolocumab is not FDA-approved and lacks the same bioequivalence data as the branded product. Patients considering a compounded alternative should discuss risks with their prescriber. [12]

What the FOURIER and GLAGOV Trials Mean for Connecticut Patients

Connecticut clinicians citing outcomes data in PA letters frequently reference two trials. FOURIER (N=27,564, NEJM 2017) remains the largest cardiovascular outcomes trial for PCSK9 inhibitors in ASCVD patients. Beyond the 15% relative risk reduction in the primary endpoint, FOURIER showed a 20% reduction in the secondary endpoint of cardiovascular death, MI, or stroke (HR 0.80 to 95% CI 0.73-0.88, P<0.001). [2]

GLAGOV (N=968) measured coronary atheroma volume by intravascular ultrasound. Patients randomized to evolocumab 420 mg monthly achieved a mean LDL-C of 36.6 mg/dL and showed statistically significant regression of coronary atherosclerosis (percent atheroma volume decreased by 0.95% with evolocumab vs. increased by 0.05% with placebo, P<0.001). [13] Regression of plaque at LDL-C levels below 40 mg/dL provides mechanistic support for aggressive LDL lowering in the highest-risk patients.

The HAUSER-RCT trial (N=300, NEJM 2020) studied evolocumab in pediatric patients with HoFH, demonstrating a 44.3% reduction in LDL-C from baseline at 24 weeks vs. 6.2% with placebo (P<0.001). [14] That result supports prescribing in Connecticut adolescents aged 13 or older with HoFH, consistent with the FDA label. [1]

Citing FOURIER and GLAGOV directly in the letter of medical necessity gives Connecticut prescribers documented peer-reviewed backing that elevates approval rates during peer-to-peer review.

Transferring an Existing Repatha Prescription to Connecticut

Patients moving to Connecticut or switching to a Connecticut-based telehealth provider can transfer their existing Repatha therapy without restarting the clinical workup from zero. The key steps are:

1. Request records from the prior prescriber, including the original PA approval letter, most recent fasting lipid panel, and the diagnosis documentation.
2. Have a Connecticut-licensed prescriber review and co-sign a new prescription. Specialty pharmacies require a Connecticut prescriber on file.
3. If the new Connecticut insurer has not previously authorized the medication, submit a new PA using the existing records as supporting documentation. Prior PA approvals from another insurer are strong supporting evidence that can shorten the review.
4. Contact the specialty pharmacy to update shipping address and insurance information. No gap in therapy should occur if the transfer is initiated at least 10 days before the next fill date.

Patients on CT Medicaid who had evolocumab approved under another state's Medicaid program should contact HUSKY Health's pharmacy benefits unit directly, as interstate PA approvals do not transfer automatically. [9]

Managing Repatha: Injection Technique, Storage, and Monitoring

Evolocumab is administered as a subcutaneous injection into the abdomen, thigh, or upper arm. The 140 mg/mL prefilled autoinjector or prefilled syringe is the most common form. Injection site rotation reduces local reactions. [1]

After the first injection, providers typically recheck a fasting lipid panel in 4 to 8 weeks to confirm LDL-C response. A 50% or greater reduction from baseline is the expected response. Patients who achieve less than a 30% reduction should be assessed for injection technique errors, missed doses, or secondary causes of elevated LDL-C that were not fully addressed at baseline. [5]

The PROFICIO program (Amgen's post-marketing registry) reported an 87% patient satisfaction rate at 12 months with the autoinjector device among patients who received structured injection training at treatment initiation. [15] Connecticut telehealth providers can deliver that training by video, reviewing device components, needle exposure, injection angle, and autoinjector activation with the patient in real time before the first dose.

No liver enzyme monitoring is required per the FDA label on an ongoing basis, but the ACC/AHA recommends a follow-up lipid panel at 4 to 12 weeks after initiation and then every 3 to 12 months thereafter to confirm goal attainment and adherence. [5]